RIP1-IN-1

• Description:

  RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM) . RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury[1].

• UNSPSC:

  12352005

• Target:

  Necroptosis; RIP kinase

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  CN1C2=CC=CC=C2OC[C@H](NC(C3=CC(C(C4=CC=CC=C4)=CC=N5)=C5C=C3)=O)C1=O

• Molecular Formula:

  C26H21N3O3

• Molecular Weight:

  423.46

• References & Citations:

  [1]Xu B, et al. Discovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice. Bioorg Chem. 2025 Mar 12;159:108365.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  RIPK1